Corticosteroids adjuvant analgesics

Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:   18 Years and older   (Adult, Senior) Sexes Eligible for Study:   All Accepts Healthy Volunteers:   No Criteria Key Inclusion Criteria:

The safety of OPDIVO was evaluated in CHECKMATE-025, a randomized open-label trial in which 803 patients with advanced RCC who had experienced disease progression during or after at least one anti-angiogenic treatment regimens received 3 mg/kg of OPDIVO by intravenous infusion every 2 weeks (n=406) or everolimus 10 mg daily (n=397) [see Clinical Studies ]. The median duration of treatment was months (range: 1 day to + months) in OPDIVOtreated patients and months (range: 6 days to + months) in everolimus-treated patients.

Register for alerts
If you have registered for alerts, you should use your registered email address as your username

  • Citation tools Download this article to citation manager Aertgeerts Bert , Agoritsas Thomas , Siemieniuk Reed A C , Burgers Jako , Bekkering Geertruida E , Merglen Arnaud et al. Corticosteroids for sore throat: a clinical practice guideline BMJ 2017; 358 :j4090
    • BibTeX (win & mac) Download
    • EndNote (tagged) Download
    • EndNote 8 (xml) Download
    • RefWorks Tagged (win & mac) Download
    • RIS (win only) Download
    • Medlars Download
    Help If you are unable to import citations, please contact technical support for your product directly (links go to external sites):

    Begin with 500 mg BID, and if the drug is tolerated, increase the dose to 1 g bid after 4 weeks. If diarrhea occurs, try 1 to g/day. Other side effects include gastrointestinal hemorrhage and perforation; increased susceptibility to infections is a consideration with all of these agents, particularly in combination with corticosteroids. Neutropenia is generally associated with doses of 2 g/day or greater. Mycophenolate mofetil eventually may replace azathioprine as the first-line immunosuppressive drug in patients with MG, but further studies are required.

    Corticosteroids adjuvant analgesics

    corticosteroids adjuvant analgesics

    Begin with 500 mg BID, and if the drug is tolerated, increase the dose to 1 g bid after 4 weeks. If diarrhea occurs, try 1 to g/day. Other side effects include gastrointestinal hemorrhage and perforation; increased susceptibility to infections is a consideration with all of these agents, particularly in combination with corticosteroids. Neutropenia is generally associated with doses of 2 g/day or greater. Mycophenolate mofetil eventually may replace azathioprine as the first-line immunosuppressive drug in patients with MG, but further studies are required.

    Media:

    corticosteroids adjuvant analgesicscorticosteroids adjuvant analgesicscorticosteroids adjuvant analgesicscorticosteroids adjuvant analgesicscorticosteroids adjuvant analgesics